Obstructive Sleep Apnea
Clinical Snapshot
Obstructive sleep apnea (OSA) is repeated collapse or narrowing of the upper airway during sleep — most often at the level of the soft palate, tongue base, or lateral pharyngeal walls — causing apneas (near-complete cessation of airflow) or hypopneas (a marked reduction in airflow with a desaturation or arousal), while the chest and diaphragm continue, and often visibly intensify, their effort to breathe against the blocked airway. It is diagnosed using the apnea-hypopnea index (AHI): an AHI of 5 or more events per hour with associated symptoms (excessive daytime sleepiness, snoring, witnessed apneas) or relevant comorbidity (hypertension, coronary disease, stroke, atrial fibrillation, type 2 diabetes), or an AHI of 15 or more events per hour regardless of symptoms, establishes the diagnosis.[1]
OSA is genuinely common and substantially underrecognized. A Canadian Thoracic Society/Canadian Sleep Society position paper cites unselected-population studies finding an AHI above 5 events/hour in roughly 24% of middle-aged men and 9% of middle-aged women, and a 2009 Public Health Agency of Canada survey in which 22% of adult Canadians (an estimated 5.4 million people) reported either being diagnosed with sleep apnea (3%) or being at high risk for it based on symptoms and risk factors (19%) — meaning the large majority of Canadians with clinically relevant OSA risk have never been formally diagnosed.[2] That gap matters directly to a pharmacist: a patient requesting a sedative-hypnotic for "trouble sleeping," an opioid for chronic pain, or an OTC sleep aid at the counter may have unrecognized OSA driving the very symptom they are asking to have treated pharmacologically — and several of the most common answers to "help me sleep" or "manage this pain" (benzodiazepines, Z-drugs, opioids, sedating antihistamines) can worsen pharyngeal collapsibility and blunt the arousal response that normally terminates an obstructive event. See Pharmacologic Treatment Options and Drug Tables for the full caution framework.
Once OSA is diagnosed and CPAP is prescribed, the single biggest determinant of whether treatment actually works is not device selection — it is adherence, and adherence is disproportionately shaped by how well early side effects (mask leak, dryness, claustrophobia, pressure intolerance) are troubleshooted in the first few weeks.[3] A pharmacist who can recognize a specific, fixable adherence barrier and either address it directly or route the patient back to their sleep/DME provider before they simply stop using the machine is intervening at the single highest-leverage point in this entire chapter.
Recognize the Condition
Mechanism: a mechanically obstructed airway, not an absent respiratory drive
During sleep, pharyngeal dilator muscle tone (genioglossus and other upper-airway muscles) normally decreases, and lung volume falls — both of which reduce the airway's cross-sectional area and the longitudinal "tracheal traction" that helps keep it open. In OSA, an anatomically narrowed or more collapsible airway — from obesity-related peripharyngeal fat deposition, retrognathia, macroglossia, tonsillar hypertrophy, or simply an unfavourable craniofacial shape — cannot compensate for this normal sleep-related loss of tone and volume, and the airway partially or completely collapses. Critically, the brainstem's respiratory drive is intact and active throughout — the diaphragm and chest wall keep trying to move air, with effort that typically increases as the obstruction persists, until an arousal (often with a gasp or snort) restores airway patency. This is the opposite pattern from central sleep apnea, where airflow and respiratory effort go flat together because the brainstem has stopped signalling the chest to move at all — see that chapter for the full mechanistic contrast and its own distinct treatment framework. Mixed events, with an initial central component followed by an obstructive one, and coexisting OSA/CSA, are both real and are covered briefly in Special Populations.
Symptoms
- Loud, habitual snoring, often with witnessed pauses, gasping, snorting, or choking arousals reported by a bed partner — though the absence of a bed partner's report does not exclude OSA, and snoring can be softer or absent in some patients, particularly thinner patients and women.
- Excessive daytime sleepiness, unrefreshing sleep despite adequate time in bed, and morning headache.
- Nocturia, decreased libido, and, in some patients, mood symptoms or cognitive complaints (difficulty concentrating, memory complaints) that are sometimes misattributed to depression, aging, or an unrelated cause before OSA is considered.
- Treatment-resistant hypertension, new or worsening atrial fibrillation, or otherwise unexplained nocturnal or early-morning cardiovascular events — each a recognized association that should prompt OSA screening even without classic sleep complaints.
Severity is defined by the apnea-hypopnea index
| Category | AHI (events/hour) |
|---|---|
| Normal | Under 5 |
| Mild OSA | 5 to under 15 |
| Moderate OSA | 15 to under 30 |
| Severe OSA | 30 or more |
Severity by itself does not fully predict symptom burden or treatment urgency — a patient with a moderate AHI and severe daytime sleepiness in a safety-critical occupation may need more urgent management than a patient with a higher AHI and minimal symptoms — but it is the standard framework used to grade disease and guide the treatment ladder in Choose Initial Treatment.[1]
Key differential considerations
- Central sleep apnea — see that chapter; distinguished on polysomnography by absent, rather than persistent, respiratory effort during events. Chronic opioid therapy and heart failure with reduced ejection fraction are its 2 classic drivers, and either can coexist with anatomic OSA in the same patient.
- Obesity hypoventilation syndrome (OHS) — daytime hypercapnia (elevated PaCO₂) in a patient with obesity and sleep-disordered breathing; frequently coexists with severe OSA but reflects a distinct, more dangerous ventilatory failure pattern that changes monitoring and, often, the choice of PAP modality — see Special Populations.
- Insufficient sleep syndrome and poor sleep hygiene — genuinely common, and can coexist with mild OSA; treating only the OSA will not resolve daytime sleepiness that is actually driven by inadequate time in bed.
- Narcolepsy and other central disorders of hypersomnolence — consider when daytime sleepiness is disproportionate to OSA severity or persists despite confirmed adequate treatment; cataplexy, sleep paralysis, and hypnagogic hallucinations point away from OSA as the sole explanation.
- Medication- or substance-induced sedation — sedating antihistamines, benzodiazepines, opioids, alcohol, and some antidepressants can all produce daytime sleepiness independent of, or in addition to, OSA; see Pharmacologic Treatment Options and Drug Tables.
Risk Factors
- Obesity, particularly central/neck adiposity — the single strongest modifiable risk factor, through peripharyngeal fat deposition narrowing the airway and reducing lung volume during sleep.
- Craniofacial and upper-airway anatomy — retrognathia/micrognathia, macroglossia, a high-arched or narrow palate, tonsillar or adenoidal hypertrophy, and a large neck circumference (STOP-Bang uses greater than 40 cm as its threshold criterion)[4] all independently narrow or destabilize the airway, and can produce clinically significant OSA even in a patient who is not obese.
- Male sex — risk in women rises substantially after menopause, approaching male rates, likely reflecting loss of the relatively protective effect of progesterone/estrogen on upper-airway muscle tone and fat distribution.
- Older age, with prevalence rising through middle age and plateauing or slightly declining in the oldest adults.
- Family history and heritable craniofacial traits.
- Nasal obstruction — septal deviation, chronic rhinitis, or nasal polyps increase upper-airway resistance and can worsen OSA and reduce CPAP tolerance.
- Endocrine conditions — hypothyroidism (macroglossia, myopathy affecting airway muscles) and acromegaly (soft-tissue and craniofacial overgrowth) are recognized, reversible-in-part contributors worth screening for in an atypical presentation.
- Pregnancy, particularly the third trimester — weight gain, upper-airway mucosal edema, and reduced functional residual capacity all increase OSA risk, with associations to gestational hypertension/pre-eclampsia and gestational diabetes; see Special Populations.
- Fluid-retaining conditions — heart failure, chronic kidney disease, and venous insufficiency can worsen OSA through nocturnal rostral fluid shift into the neck and upper airway when supine.
- Down syndrome and other craniofacial syndromes — a recognized, high-prevalence association due to macroglossia, midface hypoplasia, and hypotonia.
- Smoking and evening alcohol use — smoking promotes upper-airway inflammation and edema; alcohol relaxes pharyngeal dilator muscle tone and blunts the arousal response, worsening both the frequency and severity of obstructive events, particularly in the first several hours of sleep.
- Sedative-hypnotic, opioid, and other CNS-depressant use — relevant both as a risk factor for unmasking or worsening OSA severity and as the direct subject of Pharmacologic Treatment Options and Drug Tables.
Red Flags & Refer
Any of the following changes the plan from routine sleep-clinic scheduling to urgent action:
- Severe daytime sleepiness in a patient with a safety-critical occupation — commercial driving, operating heavy machinery, piloting, or a comparable role — needs prompt assessment and explicit interim driving-safety counselling; do not wait for the next routine sleep-clinic opening. Provincial reporting obligations for a driver whose sleepiness has caused a collision or near-miss vary — the treating clinician and, in some provinces, the licensing authority need to be involved directly.[2]
- Suspected obesity hypoventilation syndrome — an obese patient with OSA symptoms plus morning headache, unexplained lower-extremity edema, or signs suggesting cor pulmonale — needs urgent evaluation for daytime hypercapnia (venous or arterial blood gas, or an elevated serum bicarbonate as a clue) rather than being managed as routine OSA; the ventilatory-failure risk and the required PAP approach both differ. See Special Populations.
- A motor vehicle collision or a genuine near-miss attributable to sleepiness — treat as an urgent safety issue: reinforce not driving while drowsy, arrange prompt assessment, and involve the prescriber regarding any sedating medication that may be contributing.[2]
- A perioperative patient with a high STOP-Bang score and no prior OSA diagnosis scheduled for a procedure involving opioid-based anesthesia/analgesia — flag to the surgical and anesthesia team before the procedure; this changes intraoperative and postoperative monitoring, not just the anesthetic plan.[5]
- Witnessed apneic pauses with cyanosis, prolonged gasping, or difficulty rousing the patient in someone also on chronic opioid therapy — evaluate urgently for opioid toxicity/overdose as a distinct, more time-critical problem, and consider a mixed obstructive/central picture (see the Central Sleep Apnea and Opioid-Related Disorders chapters) rather than assuming this is simply known OSA.
- Severe hypoxemia on a sleep study or pulse oximetry, or a clinical picture suggesting COPD-OSA overlap syndrome — refer promptly for pulmonology assessment rather than routine sleep-clinic follow-up.
- Any patient repeatedly requesting a sedative-hypnotic, opioid dose increase, or OTC sedating sleep aid despite known, untreated, or non-adherent OSA — escalate to the prescriber rather than continuing to dispense; see Common Errors to Avoid and Algorithm C.
Assessment & Diagnosis
History and examination
Ask specifically about snoring loudness and pattern, witnessed apneas/gasping/choking, unrefreshing sleep, morning headache, and daytime sleepiness — quantified where possible with the Epworth Sleepiness Scale (0-24; a score of 10 or more suggests clinically significant sleepiness). Review comorbidities that raise pretest probability: hypertension (especially treatment-resistant), atrial fibrillation or other arrhythmia, coronary disease, stroke, type 2 diabetes, and heart failure. On examination, note BMI, neck circumference, tonsillar size, and craniofacial features (retrognathia, high-arched palate, macroglossia). Take a complete medication list, since sedative-hypnotics, opioids, and other CNS depressants both raise pretest suspicion and change the urgency of addressing the problem — see Pharmacologic Treatment Options.
STOP-Bang — the validated screening tool to use first
The STOP-Bang questionnaire, developed and validated at the University Health Network/University of Toronto, is an 8-item screening tool combining 4 symptom/history items (STOP) with 4 objective findings (BANG).[4]
| Item | Criterion (1 point each) |
|---|---|
| S — Snoring | Loud snoring (louder than talking, or loud enough to be heard through a closed door) |
| T — Tiredness | Frequent daytime tiredness, fatigue, or sleepiness |
| O — Observed apnea | Someone has witnessed you stop breathing, choke, or gasp during sleep |
| P — Pressure | Treated or untreated high blood pressure |
| B — BMI | BMI over 35 kg/m² |
| A — Age | Age over 50 years |
| N — Neck circumference | Neck circumference over 40 cm |
| G — Gender | Male |
Interpretation: a total score of 0-2 suggests low risk of OSA; 3-4, intermediate risk; 5-8, high risk.[4] A high or intermediate score does not itself diagnose OSA — it identifies who should be referred for objective testing, and a low score in a patient with a strong independent clinical suspicion (e.g., treatment-resistant hypertension, witnessed apneas) should not, by itself, be used to rule OSA out.
Objective testing — the only way to actually diagnose and grade OSA
Home sleep apnea testing (HSAT) is appropriate for adults with a high pretest probability of moderate-to-severe uncomplicated OSA and no significant comorbidity that would confound the result.[1] Full, attended polysomnography (PSG) is preferred, rather than HSAT, when there is significant cardiopulmonary disease (including suspected heart failure-associated central sleep apnea), a neuromuscular disorder, suspected hypoventilation or opioid-associated central breathing disturbance, or when a technically inadequate or unexpectedly negative HSAT does not match a strong clinical suspicion.[1][6] As in the Central Sleep Apnea chapter, most HSAT devices lack a true respiratory-effort channel, so they can quantify an AHI but generally cannot reliably distinguish obstructive from central events on their own — a relevant limitation when a mixed picture is suspected (chronic opioid therapy, known heart failure).
What the report should specify
- The overall AHI, and the proportion of events that are obstructive versus central versus mixed.
- Oxygen saturation nadir and total time spent below 90% saturation.
- Whether events cluster in the supine position (relevant to positional therapy — see Choose Initial Treatment) or in REM sleep.
- Any suggestion of hypoventilation (sustained oxygen desaturation without discrete events, or an elevated transcutaneous/end-tidal CO₂ where measured) that should prompt evaluation for obesity hypoventilation syndrome.
Treatment Targets
- Confirm the diagnosis objectively (STOP-Bang risk stratification followed by HSAT or PSG as appropriate) before committing a patient to long-term device therapy.
- Reduce the AHI to a clinically meaningful degree using a therapy the patient will actually use — adherence, not device selection alone, is the rate-limiting step for whether treatment works.
- Resolve or substantially improve daytime symptoms: excessive sleepiness, morning headache, and unrefreshing sleep.
- Support cardiometabolic risk reduction — blood pressure, glycemic control, and arrhythmia burden all plausibly benefit from effectively treated OSA, even though device therapy is not proven to be independently life-extending in every population.
- Achieve meaningful weight loss in patients with obesity-associated OSA — even a modest 5-10% body-weight reduction can meaningfully lower the AHI, and larger reductions can substantially reduce or occasionally resolve OSA.
- Systematically screen every new or renewed sedative-hypnotic, opioid, muscle-relaxant, or sedating OTC-sleep-aid request against the patient's known or suspected OSA and CPAP-adherence status before dispensing.
- Reinforce driving-safety and occupational-safety counselling in any symptomatic or newly diagnosed patient, and in any patient found to be CPAP-non-adherent, until effective treatment is re-established.
- Recognize CPAP intolerance as a solvable adherence problem in most cases, and escalate to oral appliance therapy, positional therapy, or surgical referral when troubleshooting genuinely fails, rather than writing the patient off as simply "non-compliant."
Choose Initial Treatment
Adherence — not device choice — is what determines whether CPAP works
CPAP is highly effective at correcting the AHI when it is actually worn, but non-adherence is common and is disproportionately driven by specific, fixable early problems — mask leak or discomfort, nasal dryness or congestion, claustrophobia, and pressure intolerance — that are most likely to become permanent non-use if not addressed in the first 1 to 4 weeks of therapy.[3] A pharmacist who systematically asks about these specific barriers at any early refill or consultation, rather than simply asking "how's the CPAP going," is intervening at the point with the most leverage over whether this entire chapter's mainstay therapy actually succeeds.
Practical troubleshooting by barrier:
- Nasal/oral dryness or congestion — heated humidification (built into most modern devices) is first-line and often resolves this quickly; a chin strap can help if mouth breathing causes air leak through the mouth with a nasal mask/pillow interface.
- Mask leak, discomfort, or marks — mask type (nasal pillow, nasal mask, or full-face mask) and fit are both adjustable; a poorly fitting mask is one of the most common, most fixable reasons a patient stops using an otherwise correctly prescribed device, and switching mask type or size is a reasonable first step before assuming the therapy itself has failed.
- Claustrophobia or difficulty falling asleep with the mask on — a gradual desensitization approach (wearing the mask while awake, then during a nap, before committing to a full night) and the ramp/pressure-relief features built into most devices can meaningfully improve tolerance; formal CBT-based desensitization is available through some sleep programs for persistent cases.
- Perceived pressure intolerance — auto-titrating PAP (APAP) or bilevel PAP can feel more tolerable than a fixed single-pressure CPAP setting for some patients; this is a re-titration/prescriber discussion, not something to adjust independently.
Use objective device-download data — hours of use per night and percentage of nights meeting a minimum-use threshold (commonly 4 or more hours on at least 70% of nights, the benchmark widely used in the adherence literature and by third-party payers) — rather than symptom report alone to define whether therapy is actually being used.[3]
Treatment ladder
Step-by-step approach
Step 1 — weight loss and lifestyle measures, for every patient with overweight or obesity
Foundational, not merely adjunctive: a structured weight-loss program (behavioural, and pharmacologic or bariatric-surgical for eligible patients — see Pharmacologic Treatment Options and Non-Pharmacologic Treatment) meaningfully reduces AHI and should be pursued alongside, not only after, device therapy. Advise avoiding alcohol and any unnecessary sedating medication in the hours before bed (see Pharmacologic Treatment Options), and treat significant nasal obstruction, both of which also improve device tolerance.
Step 2 — CPAP, first-line for moderate-to-severe OSA and for any OSA with significant symptoms or cardiometabolic comorbidity
1st line CPAP is the best-studied and most consistently effective therapy across OSA severities.[7][6] Pressure is set either via an in-laboratory titration study or, increasingly, using an auto-titrating device; arrange early follow-up (within the first few weeks) specifically to troubleshoot adherence barriers using the framework above, rather than waiting for a routine follow-up interval.[3]
Step 3 — oral appliance therapy for mild-to-moderate OSA, patient preference, or genuine CPAP intolerance
A custom-fitted mandibular advancement device, provided through dental sleep medicine, is a reasonable alternative to CPAP for adults with mild-to-moderate OSA, and a reasonable second-line option after documented, adequately troubleshooted CPAP intolerance in moderate-to-severe disease.[8] Efficacy should be confirmed with follow-up objective testing rather than assumed from symptom improvement alone, since oral appliances typically produce a smaller AHI reduction than CPAP.
Step 4 — positional therapy, as an adjunct or sole therapy for clearly positional mild disease
Patients whose events cluster heavily in the supine position can benefit from a positional device or technique that discourages sleeping supine; a reasonable adjunct to CPAP or oral appliance therapy, or, for genuinely positional mild OSA, a stand-alone option.
Step 5 — surgical options, for selected patients
Reserved for patients with a clear anatomic target, inadequate response to or intolerance of the above, and appropriate specialist assessment: uvulopalatopharyngoplasty and related pharyngeal procedures, maxillomandibular advancement for selected craniofacial anatomy, hypoglossal nerve stimulation (an implantable device) for CPAP-intolerant moderate-to-severe OSA meeting specific BMI/AHI selection criteria, and bariatric surgery for eligible patients with severe obesity. A pharmacist's practical role is mainly recognizing these options exist for appropriate referral discussions and correctly reconciling an implanted hypoglossal nerve stimulator on a medication/device list.
Non-Pharmacologic Treatment
- Weight loss — a structured behavioural program is first-line for every patient with overweight/obesity-associated OSA; even a modest 5-10% body-weight reduction meaningfully lowers the AHI, and bariatric surgery is a reasonable option for eligible patients with severe obesity. See Pharmacologic Treatment Options for adjunctive pharmacotherapy (tirzepatide/semaglutide) now specifically studied for AHI reduction in this population.[9]
- CPAP — first-line device therapy for moderate-to-severe OSA and for symptomatic or comorbidity-associated OSA of any severity; see Choose Initial Treatment for the full adherence-support framework, which is the actual determinant of success.[7][3]
- Oral appliance therapy — a reasonable alternative for mild-to-moderate OSA or documented CPAP intolerance, provided through dental sleep medicine, with efficacy confirmed by follow-up testing rather than assumed.[8]
- Positional therapy — for patients whose events cluster in the supine position, as an adjunct or, in genuinely positional mild disease, a stand-alone option.
- Avoidance of alcohol and unnecessary sedating medication before bed — alcohol relaxes pharyngeal dilator tone and blunts the arousal response; see Pharmacologic Treatment Options and Drug Tables for the fuller prescribing-caution framework.
- Treatment of nasal obstruction (allergic rhinitis, septal deviation) — reduces upper-airway resistance and improves both OSA severity and CPAP tolerance.
- Oropharyngeal (myofunctional) exercises — a modest-evidence adjunct that can reduce AHI and snoring in some patients, generally as a complement to, not a replacement for, the therapies above.
- Surgical options (uvulopalatopharyngoplasty and related procedures, maxillomandibular advancement, hypoglossal nerve stimulation, bariatric surgery) — for selected patients after specialist assessment; see Choose Initial Treatment.
- Objective, device-download-based follow-up — confirming actual nightly use and residual AHI, not just asking how the patient feels, at every review; see Monitoring & Follow-Up.
Special Populations
Pregnancy
OSA risk rises through pregnancy, particularly the third trimester, from weight gain, upper-airway mucosal edema, and reduced functional residual capacity, and is associated with gestational hypertension/pre-eclampsia and gestational diabetes. STOP-Bang was not developed or validated in pregnant patients specifically, so clinical suspicion (snoring, witnessed apneas, excessive sleepiness, or new/worsening hypertension) should still prompt testing even with a reassuring score. CPAP is considered safe in pregnancy and remains first-line when OSA is diagnosed. GLP-1/dual-agonist pharmacotherapy for weight management (tirzepatide, semaglutide) is not appropriate in pregnancy — counsel patients to discontinue before a planned conception per the product monograph, and refer any weight-management goal during pregnancy itself to obstetric care. Sedative-hypnotic and opioid caution (see Pharmacologic Treatment Options) is especially relevant in pregnancy given the added maternal and fetal considerations.
Breastfeeding
CPAP use is fully compatible with breastfeeding. Data on solriamfetol, armodafinil, and modafinil in breastfeeding are limited; individualized specialist input is reasonable before starting any of them in a breastfeeding patient. Data on tirzepatide/semaglutide in breastfeeding are similarly limited — individualize.
Older adults
OSA prevalence rises with age, though the strength of its independent mortality association appears to attenuate somewhat in the oldest patients; treatment is still worthwhile for symptoms, quality of life, and cardiometabolic risk. Older adults are more susceptible to the sedation, cognitive impairment, and fall risk from any CNS-depressant medication layered onto OSA-related sleep fragmentation, and are more likely to be on polypharmacy that includes one or more agents from the Drug Tables caution list — apply an even lower threshold to flag combinations for prescriber review, and prefer non-pharmacologic approaches (including CBT-based strategies) over a new sedative-hypnotic for comorbid insomnia specifically because of this added risk.
Renal impairment
Solriamfetol requires dose reduction in moderate renal impairment and should be avoided in severe renal impairment/ESRD (see Pharmacologic Treatment Options). Gabapentin and pregabalin both require renal dose adjustment, which becomes doubly relevant when either is being used alongside an opioid in a patient with OSA (see Drug Tables). Several opioids also require renal-based adjustment — see each agent's own Drug Database entry.
Hepatic impairment
Armodafinil and modafinil dosing should be adjusted with caution in significant hepatic impairment per the product monograph. Several benzodiazepines and opioids have reduced or less predictable clearance in hepatic impairment — involve a pharmacist or specialist experienced with dosing in this setting rather than adjusting empirically.
Obesity hypoventilation syndrome overlap
An obese OSA patient with daytime hypercapnia needs closer monitoring than uncomplicated OSA — bilevel PAP is often preferred over straight CPAP, weight management is prioritized even more heavily, and supplemental oxygen should never be used alone, without PAP, given the risk of worsening hypercapnia in a patient whose ventilatory drive is already compromised.
Perioperative patients
Preoperative STOP-Bang screening identifies patients who need explicit anesthesia/surgical-team flagging regardless of formal OSA diagnosis status; known or high-risk OSA patients generally warrant opioid-sparing multimodal analgesia and closer postoperative respiratory monitoring (continuous pulse oximetry where available) when opioids or sedatives are used.[5]
Patients on chronic opioid therapy
Do not assume a breathing disturbance in a patient on chronic opioids is purely obstructive — opioid-associated central and ataxic breathing patterns (see the Central Sleep Apnea chapter) are a real, dose-related, distinct phenomenon that can coexist with anatomic OSA. A mixed picture changes the workup (full PSG is generally needed to characterize it) and the treatment approach.
Commercial drivers and other safety-critical occupations
The CTS/CSS position paper found that severity of OSA alone is not a reliable predictor of collision risk and should not be used in isolation to judge fitness to drive; the decision to restrict driving rests with the licensing authority, informed by the treating clinician's assessment, documented CPAP compliance (for non-commercial drivers) or a more rigorous compliance assessment (for commercial drivers), and provincial guidance, which a pharmacist should be aware exists even though the formal determination is not a pharmacist's role.[2] Reinforce that driving safety depends on demonstrated, objectively confirmed treatment adherence, not simply having a prescription for CPAP.
Monitoring & Follow-Up
Arrange early CPAP follow-up (within the first 1 to 4 weeks) specifically to identify and troubleshoot adherence barriers before they become entrenched non-use, using the framework in Choose Initial Treatment.[3] At every follow-up, review objective device-download data — hours of use per night, percentage of nights meeting the adherence threshold, mask-leak metrics, and residual AHI reported by the device — rather than relying on the patient's subjective sense of "it's going fine."
Symptom and outcome tracking
Track the Epworth Sleepiness Scale trend, resolution of morning headache and nocturia, and blood pressure over time alongside the device data. A normalized device-reported AHI without corresponding symptom improvement, or persistent sleepiness despite a genuinely low device-reported AHI and confirmed high adherence, both warrant reassessment rather than simply continuing the current plan unchanged — see Treatment Failure/Next Step.
Re-testing after significant change
Repeat objective testing, or at minimum a detailed device-download review, after any significant weight change, CPAP pressure adjustment, switch to oral appliance or positional therapy, or new use of a wake-promoting agent — confirming the breathing pattern and AHI have actually changed is part of monitoring, not an optional extra step.
Pharmacotherapy-specific monitoring
For solriamfetol, armodafinil, or modafinil: reconfirm adequate PAP/oral-appliance adherence at every renewal — these agents should never simply be continued as a substitute for fixing inadequate device therapy — and monitor blood pressure/heart rate (solriamfetol) or mood and sleep quality more broadly. For tirzepatide/semaglutide used adjunctively: standard GLP-1/dual-agonist monitoring (GI tolerability, gallbladder and pancreatitis symptoms, glycemic monitoring if diabetic) plus explicit reassessment of AHI and PAP pressure requirements as weight changes, since substantial weight loss can meaningfully reduce or occasionally resolve OSA.[9]
Sedative-hypnotic, opioid, and muscle-relaxant renewals
Reassess a patient's OSA/CPAP-adherence status at every renewal of any agent on the Drug Tables caution list, not only at initial dispensing — a patient's adherence and risk profile can change over time even when the prescription itself has not.
Driving and occupational safety
Revisit driving-safety and occupational-safety counselling at every significant clinical change: a new diagnosis, discovered non-adherence, a medication change involving a sedating agent, or a new report of daytime sleepiness episodes while driving.[2]
Common Errors to Avoid
- Ruling out OSA because a patient "doesn't snore loudly" — snoring can be soft or absent, particularly in thinner patients and women, and its absence should never be used alone to lower suspicion.
- Treating a STOP-Bang score, or symptom impression alone, as equivalent to an objective, AHI-based diagnosis — it is a screening tool for who needs testing, not a diagnostic test itself.[4]
- Concluding CPAP "didn't work" after a single difficult night or week, without systematically troubleshooting mask fit, humidification, desensitization, and pressure mode first — most early CPAP abandonment is a fixable adherence problem, not a genuine treatment failure.[3]
- Starting a wake-promoting agent (solriamfetol, armodafinil, modafinil) for daytime sleepiness without first objectively confirming adequate PAP/oral-appliance adherence — this can mask undertreated OSA rather than address its actual cause.[7]
- Dispensing or renewing a sedative-hypnotic, opioid, or muscle relaxant to a patient with known untreated or non-adherent OSA without flagging it to the prescriber — the centrepiece prescribing-safety issue in this chapter; see Pharmacologic Treatment Options, Drug Tables, and Algorithm C.
- Recommending an OTC sedating antihistamine (e.g., a diphenhydramine-containing "PM" product) for sleep without first asking about snoring, witnessed apneas, or other OSA risk factors — a common, easy-to-miss counter-level blind spot.
- Missing obesity hypoventilation syndrome in a severely obese OSA patient with daytime hypercapnia signs, and managing it as if it were uncomplicated OSA.
- Failing to provide explicit driving-safety counselling to a newly diagnosed, symptomatic, or CPAP-non-adherent patient in a safety-critical occupation.[2]
- Assuming positional therapy or an oral appliance is "good enough" for severe OSA with significant comorbidity without an objective efficacy check.
- Continuing supplemental oxygen alone, without PAP, as OSA therapy — oxygen alone does not correct the underlying obstruction or the arousal pattern, and can worsen hypercapnia in a patient with coexisting hypoventilation.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment where relevant. Select any drug name to open its complete Pharmasist Drug Database page. The third section of this table — sedatives, opioids, and muscle relaxants — is intentionally the most detailed section in this chapter, because screening these exact prescription and OTC categories against a patient's known or suspected OSA/CPAP-adherence status is one of the highest-yield, most concrete interventions a pharmacist can make for this condition. None of these agents are contraindicated outright in every OSA patient; the message is dose-conscious caution, avoiding unnecessary combinations (especially a benzodiazepine or Z-drug together with an opioid), and confirming CPAP adherence status before renewing — not blanket avoidance.
Pharmacotherapy for Residual Excessive Daytime Sleepiness Despite Adequate CPAP Use
Reserve for patients in whom objectively confirmed, adequate PAP or oral-appliance adherence has not resolved daytime sleepiness. Never a first step, and never a substitute for confirming adherence.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Solriamfetol | Typical adult dose: 37.5 mg PO each morning on waking; titrate weekly to a maximum of 150 mg/day (75 mg/day maximum in moderate renal impairment) | Headache, nausea, decreased appetite, anxiety, insomnia, increased heart rate and blood pressure | Avoid with or within 14 days of an MAOI; use caution with other stimulant or dopaminergic/noradrenergic agents | Dose-adjust in moderate renal impairment; avoid in severe renal impairment/ESRD. Monitor blood pressure and heart rate at baseline and follow-up. |
| Armodafinil | Typical adult dose: 150-250 mg PO each morning | Headache, nausea, insomnia, anxiety, dizziness; rare serious skin reactions reported with this drug class | CYP3A4 induction reduces the effectiveness of hormonal contraceptives — counsel on a backup or alternative method; CYP2C19 inhibition can raise levels of some co-administered drugs | Same PAP-adherence-first principle as solriamfetol. Not currently a published monograph on this platform — verify current product information directly before dispensing. |
| Modafinil | Typical adult dose: 200 mg PO each morning | Headache, nausea, insomnia, anxiety | Same CYP3A4-induction/hormonal-contraceptive interaction as armodafinil | The parent racemic compound of armodafinil, with the same counselling points. |
Adjunctive Pharmacotherapy for Weight Loss in Obesity-Associated OSA
Targets the obesity driver itself rather than the airway obstruction directly. Does not replace confirmed device therapy or objective AHI reassessment as weight changes.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Tirzepatide | Typical adult dose: Subcutaneous once weekly, titrated from 2.5 mg per the product monograph to a maintenance/maximum tolerated dose of 10-15 mg | Nausea, vomiting, diarrhea, constipation; rare pancreatitis or gallbladder disease; hypoglycemia risk with concurrent insulin or a sulfonylurea | Delayed gastric emptying can affect the absorption timing of other oral medications | SURMOUNT-OSA showed a significant AHI reduction in adults with obesity and moderate-to-severe OSA, both with and without concurrent PAP use — reassess PAP pressure/AHI as weight changes. |
| Semaglutide | Typical adult dose: Subcutaneous once weekly, titrated per the product monograph to a maintenance dose | Nausea, vomiting, diarrhea, constipation; rare pancreatitis or gallbladder disease | Delayed gastric emptying can affect the absorption timing of other oral medications | Shares the same weight-loss-mediated rationale as tirzepatide; the specific OSA-outcome trial evidence (SURMOUNT-OSA) is for tirzepatide, not semaglutide specifically. |
Sedatives, Opioids, and Muscle Relaxants — Use With Caution or Avoid in Untreated or CPAP-Non-Adherent OSA
Each of these classes can worsen pharyngeal collapsibility, blunt the arousal response that normally terminates an obstructive event, or add respiratory-depressant burden on top of an already-obstructed airway. Screen every new prescription, refill, or OTC recommendation in this list against the patient's known or suspected OSA/CPAP-adherence status; escalate concerning combinations (especially a benzodiazepine or Z-drug together with an opioid) to the prescriber rather than dispensing without comment.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Zolpidem | Typical adult dose: 5-10 mg PO at bedtime (immediate-release); use the lower end of the range in women and older adults | Next-day sedation and psychomotor impairment, cognitive effects, complex sleep behaviours (sleep-driving, sleep-eating); additive respiratory depression at higher doses or in combination with other CNS depressants | Additive CNS/respiratory depression with opioids, benzodiazepines, and alcohol; CYP3A4 inhibitors raise levels | Health Canada and the FDA mandate a lower starting dose in women due to slower clearance. In a patient with known or suspected OSA, confirm CPAP adherence and consider CBT-I before initiating, and avoid combining with an opioid. |
| Zopiclone | Typical adult dose: 5-7.5 mg PO at bedtime | Bitter/metallic taste, next-day sedation and psychomotor impairment | Additive CNS/respiratory depression with opioids, benzodiazepines, and alcohol; CYP3A4-mediated interactions | A Z-drug commonly used in Canada; the same OSA-caution principles as zolpidem apply, including caution about next-morning driving. |
| Diazepam | Dosing: Highly individualized by indication; avoid initiating specifically for a sleep complaint | Profound sedation, respiratory depression, accumulation from a long-acting active metabolite (desmethyldiazepam), particularly in older adults or hepatic impairment | Marked additive respiratory depression with opioids; CYP3A4/CYP2C19 substrate | Its long half-life makes it one of the higher-risk benzodiazepines to combine with an opioid or to use in a patient with unrecognized OSA. Not indicated for primary sleep-onset insomnia — avoid using it for that indication. |
| Lorazepam | Typical adult dose: Individualized; a common anxiolytic dose is 0.5-2 mg | Sedation, respiratory depression, anterograde amnesia | Additive CNS/respiratory depression with opioids, alcohol, and other sedatives | Shorter half-life than diazepam, but still a meaningful respiratory-depressant risk when combined with an opioid in a patient with unrecognized or non-adherent OSA — common in acute-care settings, so confirm OSA status before adding an opioid or vice versa. |
| Temazepam | Typical adult dose: 15-30 mg PO at bedtime | Sedation, respiratory depression, next-day psychomotor impairment | Additive CNS/respiratory depression with opioids, other benzodiazepines, and alcohol | Specifically marketed and requested as a hypnotic for insomnia — exactly the population where unrecognized OSA is most likely to be missed because the request is framed as "help me sleep" rather than investigated. Ask about snoring/witnessed apneas before renewing. |
| Morphine | Dosing: Individualized to the patient's pain-management needs | Respiratory depression, sedation, constipation, nausea | Additive CNS/respiratory depression with benzodiazepines, gabapentinoids, sedating antihistamines, and alcohol | Chronic use also causes a distinct central/ataxic breathing pattern (see the Central Sleep Apnea chapter) that can coexist with anatomic OSA. In an OSA patient, confirm CPAP adherence and consider opioid-sparing strategies before increasing the dose. |
| Oxycodone | Dosing: Individualized to the patient's pain-management needs | Respiratory depression, sedation, constipation, nausea | Additive CNS/respiratory depression with other sedating agents; CYP3A4/CYP2D6-mediated interactions | Combination products with acetaminophen are frequently used after surgery — a setting where OSA is often undiagnosed; see Special Populations for the perioperative screening framework. |
| Fentanyl | Dosing: Individualized, with specialist titration for transdermal formulations | Profound respiratory depression; transdermal formulations have delayed onset and offset, complicating dose titration | Strong CYP3A4 substrate — interacting drugs can raise levels substantially | Transdermal patches provide continuous systemic exposure through the exact overnight hours OSA-related obstruction is occurring — a particularly important combination to flag and monitor. |
| Codeine | Dosing: Individualized to the patient's pain-management needs | Respiratory depression that is unpredictable due to CYP2D6-dependent conversion to morphine | Additive CNS/respiratory depression with other sedating agents | CYP2D6 ultra-rapid metabolizers convert codeine to morphine faster and in greater amount than expected, producing unpredictable, occasionally severe respiratory depression — a mechanism worth specifically flagging in an OSA patient, since the usual "start low" logic can still fail in this subgroup. |
| Cyclobenzaprine | Typical adult dose: 5-10 mg PO up to 3 times daily; intended for short-term use | Sedation, anticholinergic effects (dry mouth, blurred vision) | Additive CNS depression with opioids, benzodiazepines, and alcohol; serotonergic interaction risk with SSRIs/SNRIs/MAOIs | Structurally related to tricyclic antidepressants. Its sedating effect is often the actual reason a patient reports "sleeping great" on it — which can mask, rather than treat, unrecognized OSA-related sleep fragmentation. |
| Baclofen | Dosing: Individualized titration per the product monograph | Sedation, weakness, respiratory depression, particularly at high oral doses | Additive CNS/respiratory depression with opioids, benzodiazepines, and alcohol | Renal impairment significantly raises exposure and respiratory-depressant risk — check renal function before starting or continuing in an older or comorbid OSA patient. |
| Gabapentin | Dosing: Individualized, renal-adjusted | Sedation, dizziness, peripheral edema | Additive respiratory depression specifically when combined with an opioid — a well-recognized, opioid-independent interaction signal | Increasingly used as an opioid-sparing analgesic, but "opioid-sparing" can create false reassurance about respiratory safety in a patient with OSA — the interaction risk comes from the combined sedative burden, not specifically the opioid receptor. |
| Pregabalin | Dosing: Individualized, renal-adjusted | Sedation, dizziness, peripheral edema, weight gain | Same additive respiratory-depression concern as gabapentin when combined with an opioid or other CNS depressant | Same caution as gabapentin; requires renal dose adjustment. |
| Diphenhydramine | Typical adult dose: 25-50 mg; an OTC product not recommended for regular or chronic use | Marked sedation; anticholinergic effects (dry mouth, urinary retention, constipation, confusion, especially in older adults); paradoxical excitation in children | Additive CNS depression with opioids, benzodiazepines, alcohol, and other sedating antihistamines | Available OTC in many combination "PM"/sleep-aid products, so patients often do not think to mention it as a "medication" — exactly the blind spot a pharmacist is positioned to catch at the counter. Ask about snoring/witnessed apneas before recommending it, and avoid recommending it for regular or chronic insomnia regardless of OSA status given its anticholinergic burden and poor sleep-architecture profile. |
References
- Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine, American Academy of Sleep Medicine (Kapur VK, Auckley DH, Chowdhuri S, et al.). J Clin Sleep Med 2017;13(3):479-504
- Obstructive Sleep Apnea and Driving: A Canadian Thoracic Society and Canadian Sleep Society Position Paper — Canadian Respiratory Journal, Canadian Thoracic Society and Canadian Sleep Society (Ayas N, Skomro R, Blackman A, et al.). Can Respir J 2014;21(2):114-123
- Adherence to Continuous Positive Airway Pressure Therapy: The Challenge to Effective Treatment — Proceedings of the American Thoracic Society (Weaver TE, Grunstein RR). Proc Am Thorac Soc 2008;5(2):173-178
- STOP Questionnaire: A Tool to Screen Patients for Obstructive Sleep Apnea — Anesthesiology, University Health Network/University of Toronto (Chung F, Yegneswaran B, Liao P, et al.). Anesthesiology 2008;108(5):812-821
- Society of Anesthesia and Sleep Medicine Guidelines on Preoperative Screening and Assessment of Adult Patients With Obstructive Sleep Apnea — Anesthesia and Analgesia (Chung F, Memtsoudis SG, Ramachandran SK, et al.). Anesth Analg 2016;123(2):452-473
- Canadian Thoracic Society 2011 Guideline Update: Diagnosis and Treatment of Sleep Disordered Breathing — Canadian Respiratory Journal, Canadian Thoracic Society Sleep Disordered Breathing Committee (Fleetham J, Ayas N, Bradley D, et al.). Can Respir J 2011;18(1):25-47
- Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine, American Academy of Sleep Medicine (Patil SP, Ayappa I, Caples SM, et al.). J Clin Sleep Med 2019;15(2):335-343
- Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015 — Journal of Clinical Sleep Medicine, American Academy of Sleep Medicine and American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al.). J Clin Sleep Med 2015;11(7):773-827
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity — New England Journal of Medicine, SURMOUNT-OSA Investigators (Malhotra A, Grunstein RR, Fietze I, et al.). N Engl J Med 2024;391(13):1193-1205
- Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial — American Journal of Respiratory and Critical Care Medicine (Schweitzer PK, Rosenberg R, Zammit GK, et al.). Am J Respir Crit Care Med 2019;199(11):1421-1431
- Effects of Armodafinil in the Treatment of Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome: A 12-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study in nCPAP-Adherent Adults — Clinical Therapeutics (Roth T, White D, Schmidt-Nowara W, et al.). Clin Ther 2006;28(5):689-706
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.